Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Up 460.5% in August

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a significant growth in short interest in August. As of August 14th, there was short interest totaling 119,287 shares, a growth of 460.5% from the July 30th total of 21,284 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average trading volume of 927,154 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SLXN. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold”.

Silexion Therapeutics Price Performance

NASDAQ:SLXN traded up $0.01 during mid-day trading on Thursday, hitting $0.36. 274,460 shares of the company’s stock traded hands, compared to its average volume of 611,302. Silexion Therapeutics has a 12 month low of $0.35 and a 12 month high of $80.00. The firm has a 50 day moving average of $1.90 and a two-hundred day moving average of $7.37.

Silexion Therapeutics (NASDAQ:SLXN) last released its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03. Research analysts predict that Silexion Therapeutics will post -45.5 earnings per share for the current year.

Institutional Trading of Silexion Therapeutics

An institutional investor recently bought a new position in Silexion Therapeutics stock. Ancora Advisors LLC acquired a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned 7.14% of Silexion Therapeutics at the end of the most recent quarter. 10.95% of the stock is owned by institutional investors and hedge funds.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.